Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Neurosci ; 33(42): 16778-89, 2013 Oct 16.
Article in English | MEDLINE | ID: mdl-24133278

ABSTRACT

NMDA receptor activity is involved in shaping synaptic connections throughout development and adulthood. We recently reported that brief activation of NMDA receptors on cultured ventral midbrain dopamine neurons enhanced their axon growth rate and induced axonal branching. To test whether this mechanism was relevant to axon regrowth in adult animals, we examined the reinnervation of dorsal striatum following nigral dopamine neuron loss induced by unilateral intrastriatal injections of the toxin 6-hydroxydopamine. We used a pharmacological approach to enhance NMDA receptor-dependent signaling by treatment with an inhibitor of glycine transporter-1 that elevates levels of extracellular glycine, a coagonist required for NMDA receptor activation. All mice displayed sprouting of dopaminergic axons from spared fibers in the ventral striatum to the denervated dorsal striatum at 7 weeks post-lesion, but the reinnervation in mice treated for 4 weeks with glycine uptake inhibitor was approximately twice as dense as in untreated mice. The treated mice also displayed higher levels of striatal dopamine and a complete recovery from lateralization in a test of sensorimotor behavior. We confirmed that the actions of glycine uptake inhibition on reinnervation and behavioral recovery required NMDA receptors in dopamine neurons using targeted deletion of the NR1 NMDA receptor subunit in dopamine neurons. Glycine transport inhibitors promote functionally relevant sprouting of surviving dopamine axons and could provide clinical treatment for disorders such as Parkinson's disease.


Subject(s)
Axons/metabolism , Corpus Striatum/metabolism , Dopaminergic Neurons/metabolism , Glycine Plasma Membrane Transport Proteins/metabolism , Parkinson Disease, Secondary/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , Behavior, Animal/physiology , Glycine Plasma Membrane Transport Proteins/genetics , Mesencephalon/metabolism , Mice , Motor Skills/physiology , Oxidopamine , Parkinson Disease, Secondary/chemically induced , Recovery of Function/physiology , Substantia Nigra/metabolism
2.
Nat Commun ; 15(1): 3816, 2024 May 20.
Article in English | MEDLINE | ID: mdl-38769293

ABSTRACT

SARS-CoV-2 infection causes severe pulmonary manifestations, with poorly understood mechanisms and limited treatment options. Hyperferritinemia and disrupted lung iron homeostasis in COVID-19 patients imply that ferroptosis, an iron-dependent cell death, may occur. Immunostaining and lipidomic analysis in COVID-19 lung autopsies reveal increases in ferroptosis markers, including transferrin receptor 1 and malondialdehyde accumulation in fatal cases. COVID-19 lungs display dysregulation of lipids involved in metabolism and ferroptosis. We find increased ferritin light chain associated with severe COVID-19 lung pathology. Iron overload promotes ferroptosis in both primary cells and cancerous lung epithelial cells. In addition, ferroptosis markers strongly correlate with lung injury severity in a COVID-19 lung disease model using male Syrian hamsters. These results reveal a role for ferroptosis in COVID-19 pulmonary disease; pharmacological ferroptosis inhibition may serve as an adjuvant therapy to prevent lung damage during SARS-CoV-2 infection.


Subject(s)
COVID-19 , Ferroptosis , Lung , Mesocricetus , SARS-CoV-2 , COVID-19/virology , COVID-19/metabolism , COVID-19/pathology , Animals , Humans , Male , Lung/pathology , Lung/virology , Lung/metabolism , SARS-CoV-2/physiology , Female , Iron/metabolism , Middle Aged , Disease Models, Animal , Aged , Lung Injury/virology , Lung Injury/metabolism , Lung Injury/pathology , Iron Overload/metabolism , Adult , Cricetinae
3.
Nat Commun ; 14(1): 3959, 2023 07 05.
Article in English | MEDLINE | ID: mdl-37402814

ABSTRACT

Prophylactic vaccines for SARS-CoV-2 have lowered the incidence of severe COVID-19, but emergence of viral variants that are antigenically distinct from the vaccine strains are of concern and additional, broadly acting preventive approaches are desirable. Here, we report on a glycolipid termed 7DW8-5 that exploits the host innate immune system to enable rapid control of viral infections in vivo. This glycolipid binds to CD1d on antigen-presenting cells and thereby stimulates NKT cells to release a cascade of cytokines and chemokines. The intranasal administration of 7DW8-5 prior to virus exposure significantly blocked infection by three different authentic variants of SARS-CoV-2, as well as by respiratory syncytial virus and influenza virus, in mice or hamsters. We also found that this protective antiviral effect is both host-directed and mechanism-specific, requiring both the CD1d molecule and interferon-[Formula: see text]. A chemical compound like 7DW8-5 that is easy to administer and cheap to manufacture may be useful not only in slowing the spread of COVID-19 but also in responding to future pandemics long before vaccines or drugs are developed.


Subject(s)
COVID-19 , Influenza Vaccines , Influenza, Human , Mice , Animals , Humans , SARS-CoV-2 , COVID-19/prevention & control , COVID-19 Vaccines
4.
Sci Transl Med ; 14(646): eabn6859, 2022 05 25.
Article in English | MEDLINE | ID: mdl-35438546

ABSTRACT

The devastation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, we identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies with other receptor-binding domain (RBD)-directed antibodies showed 10-40 to have the greatest breadth against sarbecoviruses, suggesting that 10-40 is a promising agent for pandemic preparedness. Moreover, structural analyses on 10-40 and similar antibodies not only defined an epitope cluster in the inner face of the RBD that is well conserved among sarbecoviruses but also uncovered a distinct antibody class with a common CDRH3 motif. Our analyses also suggested that elicitation of this class of antibodies may not be overly difficult, an observation that bodes well for the development of a pan-sarbecovirus vaccine.


Subject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Viral , Humans , Immunoglobulin Isotypes , Spike Glycoprotein, Coronavirus
5.
Neuron ; 83(5): 1131-43, 2014 Sep 03.
Article in English | MEDLINE | ID: mdl-25155956

ABSTRACT

Developmental alterations of excitatory synapses are implicated in autism spectrum disorders (ASDs). Here, we report increased dendritic spine density with reduced developmental spine pruning in layer V pyramidal neurons in postmortem ASD temporal lobe. These spine deficits correlate with hyperactivated mTOR and impaired autophagy. In Tsc2 ± ASD mice where mTOR is constitutively overactive, we observed postnatal spine pruning defects, blockade of autophagy, and ASD-like social behaviors. The mTOR inhibitor rapamycin corrected ASD-like behaviors and spine pruning defects in Tsc2 ± mice, but not in Atg7(CKO) neuronal autophagy-deficient mice or Tsc2 ± :Atg7(CKO) double mutants. Neuronal autophagy furthermore enabled spine elimination with no effects on spine formation. Our findings suggest that mTOR-regulated autophagy is required for developmental spine pruning, and activation of neuronal autophagy corrects synaptic pathology and social behavior deficits in ASD models with hyperactivated mTOR.


Subject(s)
Autistic Disorder/pathology , Autophagy/physiology , Dendritic Spines/genetics , Neurons/pathology , Synapses/pathology , TOR Serine-Threonine Kinases/metabolism , Adolescent , Age Factors , Animals , Autistic Disorder/genetics , Autophagy/drug effects , Child , Child, Preschool , Disease Models, Animal , Exploratory Behavior/physiology , Female , Humans , Immunosuppressive Agents/pharmacology , Male , Mice , Mice, Transgenic , Neurons/drug effects , Sirolimus/pharmacology , Synapses/drug effects , Temporal Lobe/pathology , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/deficiency , Tumor Suppressor Proteins/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL